



HAL
open science

Minor Bleeds Alert for Subsequent Major Bleeding in Patients Using Vitamin K Antagonists.

Nic J.G.M. Veeger, Margriet Piersma-Wichers, Karina Meijer, Hans L. Hillege

► **To cite this version:**

Nic J.G.M. Veeger, Margriet Piersma-Wichers, Karina Meijer, Hans L. Hillege. Minor Bleeds Alert for Subsequent Major Bleeding in Patients Using Vitamin K Antagonists.. *British Journal of Haematology*, 2011, 153 (4), pp.508. 10.1111/j.1365-2141.2011.08656.x . hal-00625169

HAL Id: hal-00625169

<https://hal.science/hal-00625169>

Submitted on 21 Sep 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Minor Bleeds Alert for Subsequent Major Bleeding in Patients Using Vitamin K Antagonists.

Journal:	<i>British Journal of Haematology</i>
Manuscript ID:	BJH-2010-01799.R1
Manuscript Type:	Ordinary Papers
Date Submitted by the Author:	17-Feb-2011
Complete List of Authors:	Veeger, Nic J.G.M.; University Medical Centre Groningen, Epidemiology Piersma-Wichers, Margriet; Thrombosis Service Groningen, -- Meijer, Karina; University Medical Centre Groningen, Haematology Hillege, Hans L.; University Medical Centre Groningen, Epidemiology
Key Words:	Vitamin K antagonists, Minor Haemorrhage, Major Haemorrhage, Prevention, ANTICOAGULANTS

1
2
3
4
5 **Minor Bleeds Alert for Subsequent Major Bleeding in Patients Using Vitamin K**
6
7 **Antagonists.**
8
9

10
11 Running short title: Minor Bleeds Alert for Major Bleeding
12
13

14
15 Authors: Nic J.G.M. Veeger, PhD ^{1,2}; Margriet Piersma-Wichers, MD ^{1,3} Karina Meijer, MD,
16
17 PhD ¹; Hans L. Hillege, MD, PhD ².
18

19
20 Department of Haematology, Division of Haemostasis and Thrombosis (1), Trial Coordination
21
22 Centre, Department of Epidemiology (2), University Medical Centre Groningen - University of
23
24 Groningen, Thrombosis Service Groningen (3), The Netherlands.
25
26

27
28 word count: 3304 summary: 200
29
30

31
32
33 Corresponding author

34
35 N.J.G.M. Veeger

36
37 Trial Coordination Centre, Department of Epidemiology,

38
39 University Medical Centre Groningen

40
41 P.O.Box 30 001, 9700 RB, Groningen

42
43 Tel. +31 50 361 8064 (8061); Fax +31 50 361 8062

44
45 E-mail address: N.Veeger@tcc.umcg.nl
46
47
48
49

50
51 We would like to acknowledge prof.dr. Jan van der Meer who died last year. His contribution
52
53 to our study was of utmost importance.
54
55

56
57 Financial disclosure: None of the authors had an affiliation with or financial involvement with
58
59 any organisation or entity with a financial interest in or financial conflict with the subject
60
matter or materials discussed in the manuscript.

SUMMARY

Vitamin K antagonists (VKA) have shown to be effective in primary and secondary prevention of thromboembolism, but the associated risk of bleeding is an important limitation. The majority of the bleeds are clinically mild. In this study, we assessed whether these minor bleeds are associated with major bleeding, when controlling for other important risk indicators, including the achieved quality of anticoagulation. For this, 5898 patients of a specialised anticoagulation clinic were retrospectively studied for one year after initiation of VKA therapy. The risk of major bleeding was estimated using a multivariable piecewise exponential model with time-varying exposure for occurring minor bleeds.

In patients with a minor bleed (N=1015) subsequent major bleeding occurred more frequently than in patients without a minor bleed (N=4883), with an incidence rate of 2.3 (95%CI 1.4-3.7) versus 1.2 per 100 person-years (95%CI 0.9-1.7). The adjusted relative risk of subsequent major bleeding after a minor bleed was 2.9 (95%CI 1.1-7.2, P=0.024). The percentage of time above INR 5 was also independently associated with major bleeding, with a 2.2-fold increased risk in patients with at least 9% of time above INR 5 (95%CI 1.3-4.0, P=0.006).

Minor bleeds alert for subsequent major bleeding, independent of the quality of anticoagulation.

Keywords: Anticoagulants; Vitamin K antagonists; Prevention; Minor Haemorrhage; Major Haemorrhage.

INTRODUCTION

Vitamin K antagonists (VKA) are widely used in primary and secondary prevention of thromboembolism. Although these drugs have shown to be effective, the associated risk of bleeding is an important limitation (Schulman *et al*, 2008). Both effectiveness and risk of bleeding are related to the actual level of anticoagulation, expressed by the international normalized ratio (INR) (Schulman *et al*, 2008; Veeger *et al*, 2005). The intensity of anticoagulation widely varies within and between patients, due to environmental and genetic factors (Wilkinson, 2005; Ansell *et al*, 2008; Kucher *et al*, 2004; Wittkowsky & Devine, 2004; Wittkowsky, 2005; Palareti *et al*, 2005; Penning-van Beest *et al*, 2001), as well as patients' compliance (van der Meer *et al*, 1997; McCormick *et al*, 2001). In this respect, the individual time spend below, within and above the INR target range can be used to identify patients on VKA who are at high risk of (recurrent) thromboembolism and bleeding (Veeger *et al*, 2005; Veeger *et al*, 2006).

Due to the above mentioned variability, a continued monitoring of the level of anticoagulation is mandatory. In the Netherlands, a unique nationwide network of 61 specialized anticoagulation clinics is responsible for the VKA management of all outpatients. In these specialized clinics, experienced physicians and dosing assistants are involved in optimizing VKA therapy, using computerized dosing programs and protocols for dose adjustments in case of under- and over-anticoagulation.

In assessing the risk of bleeding while using VKA, the primary focus is on major bleeding (Schulman *et al*, 2008). An important risk factor for major bleeding is the achieved level of anticoagulation. A previous major bleeding is also identified as a risk factor for subsequent major bleeding, although not consistently in all studies (The Stroke Prevention in Atrial Fibrillation Investigators, 1996; Beyth *et al*, 1998; Kuijter *et al*, 1999; White *et al*, 1996; Shireman *et al*, 2006). For a minor bleeding such an association has not yet been demonstrated. Minor bleeding might be due to over-anticoagulation or a pre-existing mild

1
2
3
4
5 bleeding disorder, which is enhanced by VKA. In either case, the occurrence of a minor
6
7 bleed during VKA therapy could alert for a high risk situation necessitating a renewed risk-
8
9 benefit assessment of the VKA therapy in those patients.
10

11 In this study, we hypothesized that after a minor bleed, patients are at increased risk
12
13 for subsequent major bleeding.
14
15

16 17 18 **METHODS**

19 20 21 **Patients and study design**

22
23 Patients originated from an inception cohort of 6758 consecutive patients referred to a large
24
25 Dutch community based anticoagulation clinic for management of their VKA therapy from
26
27 January 1st, 1995 to February 1st, 1998. During this period, data on level of anticoagulation,
28
29 as well as bleeding complications was prospectively collected during the course of the VKA
30
31 therapy by the anticoagulation clinic during the regular visits. The cohort is described in
32
33 greater detail previously (Veeger *et al*, 2005; Veeger *et al*, 2006).
34
35
36

37 To assess the effect of the minor bleeds on the occurrence of subsequent major
38
39 bleeding, we used the data of all patients collected over a period of 12 months after their first
40
41 INR measurement by the anticoagulation clinic, or until the end of their treatment in case of a
42
43 treatment duration of less than 12 months. To be able to fully address the possible
44
45 association between minor and subsequent major bleeding in a time-dependent setting the
46
47 minimum treatment duration was set to one month. Of the 6758 consecutive patients, 860
48
49 patients were excluded due to a late entry in the original cohort resulting in a treatment
50
51 duration of less than one month (N=228), a discontinuation of VKA therapy within the first
52
53 month (N=549), an early major bleeding (N=22; 6 fatal) or death due to a non-bleeding cause
54
55 within the first month (N=61). Thereby, our study population consisted of 5898 patients
56
57 treated with VKA for at least one month (N=1361, deep vein thrombosis; N=603, pulmonary
58
59
60

1
2
3
4
5 embolism; N=2328, atrial fibrillation; N=842, myocardial infarction; N=764, prosthetic heart
6
7 valve).

11 **Data collection**

13 *Patients' characteristics*

14
15 Patients' characteristics were collected from the records on file at the anticoagulation clinic.

16
17 Baseline data included age, sex, co-morbidity, concomitant drugs and indication for VKA
18
19 therapy.

24 *Anticoagulation data*

25
26 INR target range, as recommended by the Dutch Federation of Anticoagulation Clinics, was
27
28 2.5 to 3.5 in patients with venous thromboembolism or atrial fibrillation, and 3.0 to 4.0 in
29
30 patients with myocardial infarction. In patients with a prosthetic heart valve, up to January 1st
31
32 1997 the target range was INR 3.5 to 4.8. From January 1st 1997 onwards, it was lowered to
33
34 INR 3.0 to 4.0. In all patients, VKA dosing was performed using a nomogram based
35
36 automated system, with control by experienced physicians. INR was measured once every 3
37
38 to 4 weeks or more frequently when appropriate, by the central laboratory of the
39
40 anticoagulation clinic. In the initial phase, INR was checked more frequently, i.e. every 3 to 5
41
42 days. The dose was increased with predefined dose steps at INR values below the target
43
44 range, and tapered at INR values exceeding the target range but less than 6.4. Treatment
45
46 was interrupted for one day at INR values above 6.4 and vitamin K was additionally given in
47
48 case of INR > 10.0. The next measurement of INR was then performed within 3 days. The
49
50 VKA of first choice was acenocoumarol. All data regarding anticoagulant therapy was stored
51
52 in a computerized registration system. INR values, dates of measurements and dosage
53
54 schedules were extracted from this system.
55
56
57
58
59
60

Adverse events

1
2
3
4
5 The physicians of the anticoagulation clinic registered all major bleeds, as a mandatory part
6
7 of their quality system. Within the unique setting of VKA management in the Netherlands,
8
9 patient education and awareness regarding the risks of VKA therapy also included reporting
10
11 the occurrence of minor bleeds to the treating physicians. These bleeds were recorded. If
12
13 treatment was interrupted due to a minor bleed, this was included. For this study, all
14
15 information about major and minor bleeds, hospital admissions, treatment interruptions or
16
17 cessation, and death during the treatment period was collected by the anticoagulation clinic.
18
19 To minimize misclassification, all bleeding reports were adjudicated by an experienced
20
21 haematologist who was not informed about the level of anticoagulation, nor about the
22
23 occurrence of previous events, to assure a blinded classification.
24
25
26
27

28 29 **Clinical outcome**

30
31 Endpoints of clinical outcome were major and minor bleeds. Major bleeding was defined as a
32
33 clinically overt bleed leading to transfusion, hospitalization and/or death, or a retroperitoneal,
34
35 intracranial or intra-ocular bleed (Schulman & Kearon, 2005). All reported overt bleeds that
36
37 did not fulfil the criteria for major bleeding were classified as minor and included in the
38
39 analysis as such. When a minor bleed required any medical intervention, it was classified as
40
41 clinically relevant minor bleed.
42
43
44
45

46 47 **Statistical analysis**

48
49 Based on actual INR values, the day-to-day INR values were calculated by linear estimation,
50
51 as proposed by Rosendaal et al with an adjustment of estimated values towards the next
52
53 actual INR value (Veeger *et al*, 2005; Rosendaal *et al*, 1993). Linear estimation was not
54
55 performed when time between to two assessments was more than 8 weeks, since the
56
57 assumption of linearity was no longer judged as valid (Azar *et al*, 1996). From these day-to-
58
59 day INR values, the amount of over-anticoagulation was estimated. For this, the percentage
60
of time above INR 5.0 was calculated for each individual patient. A cut-off value of INR 5.0

1
2
3
4
5 was chosen as above this level, the increase in the risk of major bleeding is clearly
6
7 demonstrated (Veeger *et al*, 2005).

8
9 Those patients with the highest percentages of time above INR 5.0 were classified as “over-
10
11 anticoagulated”. For this the upper quartile was a-priori defined. In these calculations, INR
12
13 data after a major bleed was not included.
14

15
16 Absolute risks (incidence rates per 100 person years) of minor and major bleeding
17
18 were assessed. Ninety-five percent confidence intervals (95%CI) around the incidence rates
19
20 were calculated under the Poisson distribution assumption. In these calculations, the post-
21
22 event follow-up time was not included.
23

24
25 The effect of over-anticoagulation (highest quartile of percentage time above INR 5.0) and
26
27 minor bleeding on the risk of major bleeding was assessed using a piecewise exponential
28
29 survival analysis approach. In this, the time at risk was divided into 11 one-month periods. As
30
31 part of the piecewise exponential survival analysis, the acceptance of the exponential model,
32
33 i.e. a constant hazard of major bleeding over the total study interval, was addressed (Allison,
34
35 1995).
36

37
38 Over-anticoagulation was assessed for each period. Minor bleeding was also incorporated in
39
40 this analysis as a monthly-varying variable, in which the exposure status of the previous
41
42 month was used to assess the associated risk of major bleeding.
43

44
45 In the multivariable analyses, sex, age, co-morbidity, concomitant drugs and
46
47 indication for VKA therapy were included as potential confounders.
48
49

50
51 Reported P-values are two-sided and a P-value < 0.05 was considered statistically
52
53 significant. For all analyses, commercially available computer software (Statistical Analysis
54
55 System version 9.2, SAS Institute, Cary, NC) was used.
56
57
58
59
60

RESULTS

In total, 5898 consecutive patients were included in our study. Their characteristics and anticoagulation data are summarized in Table 1. Cumulative treatment time was 3892 patients-years, during which 117854 INR measurements were performed.

Acenocoumarol was the predominantly used VKA (97%). The remaining patients used phenprocoumon (2%) or switched VKA during their treatment period (1%). VKA was combined with low dose aspirin in 3% of patients. Median treatment time was 9.1 months (90% central range, 1.4-11.8), during which 20 INR measurements were performed (median, 90% central range, 7-35). Based on all the actual measurements, median INR was 3.0 (90% central range, 1.6-5.7). At a patient level, the median percentage of time spend above INR 5.0 was 3% (90% central range 0-23). When considering the patients that were classified as "over-anticoagulated" (i.e. a-priori defined as the upper quartile of patients with a highest amount of time above INR 5.0), these patients were at least 9% of their treatment time above INR 5.0 (median percentage of time above INR 5.0 = 15% (90% central range 9-36).

Clinical outcome

Minor bleeding

A total of 1501 minor bleeds occurred in 1015 of 5898 patients (17%), 716 patients had a single minor bleed (71%), 194 patients two minor bleeds (19%), and 105 patients multiple recurrent minor bleeds (10%). The median INR at the time of the minor bleed was 3.3 (90% central range 1.9-6.5). The absolute risk, expressed as the incidence rate per 100 person-years was 29.6 (95%CI, 27.8-31.4). Haematomas (40%), nose bleeds (27%), conjunctiva bleeds (11%) and haematuria (10%) were the most frequently observed minor bleeds (Table 2). There was a difference in the occurrence of minor bleeds between women and men, mainly due to a difference in the number of haematomas and nose bleeds, with 418 and 241 in women vs. 177 and 167 in men. This resulted in a higher observed risk of minor bleeding

1
2
3
4
5 in women than men (incidence rates 37.1, 95%CI, 34.1-40.2 in women vs. 23.1, 95%CI,
6
7 21.0-25.4 in men; rate ratio 1.6, 95%CI 1.4-1.8, $P < 0.001$).

8
9 A medical intervention, including temporary interruption, was required for 73 minor
10
11 bleeds in 64 patients. These minor bleeds were classified as clinically relevant.
12
13

14 15 16 *Major bleeding*

17
18 Major bleeding occurred in 56 patients (0.9%), with an incidence rate of 1.4 per 100 person-
19
20 years (95% CI, 1.1-1.9). Nine major bleeds were fatal. The type of major bleeding is
21
22 presented in Table 3. The level of anticoagulation at the time of major bleeding, expressed
23
24 as the median INR was 3.4 (90% central range 1.9-9.6).
25
26

27 28 29 *Prediction of major bleeding*

30
31 A higher risk of major bleeding was observed in the patients with a minor bleed. The
32
33 incidence rate in these patients was 2.3 per 100 person-years (95%CI, 1.4-3.7), whereas in
34
35 patients without a prior minor bleed the incidence rate was 1.2 per 100 person-years (95%
36
37 CI, 0.9-1.7). The incidence rate of major bleeding after a minor bleed was 3.9 per 100
38
39 person-years (95%CI, 2.3-6.2). In this, follow-up time was restricted to the post-minor bleed
40
41 period. Notably, in the 64 patients in whom a clinically relevant bleed had occurred, for which
42
43 they received a medical intervention, including temporary interruption, major bleeding did not
44
45 occur.
46
47

48
49 In addition, we performed a sensitivity analysis on the risk of major bleeding after a
50
51 minor bleed, excluding the haematomas. This is especially relevant as to some degree
52
53 misclassification of minor bleeds might have occurred. When excluding haematomas, in
54
55 patients with a minor bleed the incidence rate of major bleeding was 2.6 per 100 person-
56
57 years (95%CI, 1.4-4.6). In the patients with a haematoma this was 1.9 (95% CI, 0.7-4.2), not
58
59 statistically significantly different (rate ratio 1.4 (95%CI, 0.5-4.0, $P = 0.53$). When taking only
60

1
2
3
4
5 the time after the minor bleed into consideration, incidence rates were 4.3 (95%CI, 2.2-7.5)
6
7 and 3.3 (95%CI, 1.2-7.2), respectively (rate ratio 1.3; 95%CI, 0.5-3.7, P = 0.63).
8
9

10
11 Furthermore, also in the “over-anticoagulated” patients (highest quartile, more than
12
13 9% of treatment time above INR 5.0), major bleeding was more frequently observed. The
14
15 incidence rate in these patients was 1.9 per 100 person-years (95% CI, 1.2-3.0), whereas in
16
17 the patients in the lower three quartiles this was 1.2 (95% CI, 0.9-1.7).
18

19
20 The adjusted relative risks associated with minor bleeding and over-anticoagulation
21
22 were estimated using a multivariable piecewise exponential model. Both over-anticoagulation
23
24 and prior minor bleeding were considered as time-dependent risk indicators, in which
25
26 exposure as assessed for each 30-day period.
27

28
29 As shown in Figure 1, a minor bleed was an independent risk indicator with a 2.9-fold
30
31 increased risk of major bleeding during the following month (HR=2.9, 95% CI, 1.1-7.2, P =
32
33 0.024). “Over-anticoagulation” was associated with a 2.2-fold increased risk of major
34
35 bleeding (HR=2.2, 95% CI, 1.3-4.0, P = 0.006). Additional independent risk indicators
36
37 identified by multivariable analysis were diabetes mellitus, malignancy, use of diuretics (time-
38
39 dependent) and age above 70 years. Model evaluation resulted in acceptance of the
40
41 exponential model (Lagrange multiplier test; P=0.12), indicating that the hazard of major
42
43 bleeding was constant over the one-year interval.
44

45
46 After excluding the haematomas, piecewise exponential survival analysis resulted in a
47
48 crude hazard ratio for the risk of major bleeding after a minor bleed of 4.1 (95%CI, 1.5-11.4,
49
50 P = 0.007). After adjustment this reduced to 3.8 (95%CI, 1.4-10.6, P = 0.010).
51
52

53
54 An additional analysis was performed using an exposure duration of two months. The
55
56 crude hazard ratio for prior minor bleeding over the two-month period was 3.5 (95%CI 1.7-
57
58 7.7, P = 0.001). The adjusted hazard ratio was 3.3 (95%CI 1.5-7.0, P = 0.002), indicating that
59
60 the increased risk lasts over the one-month period.

DISCUSSION

To our knowledge, this study is the first to specifically address minor bleeding as potential risk indicator for major bleeding. We showed that the occurrence of a minor bleeding was associated with a 2.9-fold increased risk of major bleeding in the following month. This increased risk was independent of the amount of over-anticoagulation.

The absolute risk of major bleeding in our study was 1.4 per 100 person-years. Taking into consideration that our cohort consisted of unselected patients in whom VKA therapy was managed for one year by a specialized anticoagulation clinic, this absolute risk is in line with the rates reported previously (Schulman *et al*, 2008; Ansell *et al*, 2008; van der Meer *et al*, 1993; Palareti *et al*, 1996; van Es *et al*, 2002; Linkins *et al*, 2003; Palareti & Cosmi, 2009). Our rate of minor bleeding of 29.6 per 100 person-years is more difficult to compare. In a recent large clinical trial in AF patients the rate of minor bleeding was 18.2 (Connolly *et al*, 2009). Two other large trials reported higher incidence rates for combined major and minor bleeding, ranging from 30 to 47 per 100 person-years (Albers *et al*, 2005; Olsson, 2003).

Our finding regarding the quality of anticoagulation as risk indicator is consistent with previous studies, where the association between quality of anticoagulation and major bleeding was clearly demonstrated (Reynolds *et al*, 2004; Samsa *et al*, 2002).

Some limitations must be considered. Firstly, our study cohort consisted of patients treated more than 10 years ago. This could have resulted in “outdated” findings, and thereby limiting the generalisability of our findings. However, both the type of VKAs used and the strategy that was applied to achieve optimal anticoagulation in our study are still used in current practice, making our findings still applicable for current VKA therapy.

Unfortunately, at the time of data collection, information on important genetic factors related to the individual sensitivity to VKA (Gage & Lesko, 2008; Hermida *et al*, 2002) was not available. Another limitation is the potential underreporting of bleeding complications in a

1
2
3
4
5 study in which complications are collected during the course of regular treatment. However,
6
7 we only included “new” patients and not those already on VKA at the time of the start of the
8
9 study and we had access to detailed information regarding all bleeding complications during
10
11 the one year of follow-up, including the minor bleeds. Furthermore, minor bleeds were
12
13 assessed by the experienced staff of the anticoagulation clinic responsible for monitoring the
14
15 VKA therapy and/or reported spontaneously by the patients themselves. Therefore, in our
16
17 opinion underreporting was very limited, which is also indicated by the observed bleeding risk
18
19 that is consistent with previous reports (Schulman *et al*, 2008; Palareti *et al*, 1996; van der
20
21 Meer *et al*, 1993; Albers *et al*, 2005; Connolly *et al*, 2009; Linkins *et al*, 2003; Olsson, 2003;
22
23 Palareti & Cosmi, 2009; DiMarco *et al*, 2005; Go *et al*, 2003; Hylek *et al*, 2007). This is also
24
25 supported by the sensitivity analysis excluding the haematoma, which are most prone for
26
27 misclassification. In this respect, the associated risk after a haematoma was lower than after
28
29 another type of minor bleed, although not significant. We can only speculate that this
30
31 difference can be attributed to the “smaller” haematomas. However, as additional information
32
33 on the size of haematomas was not available, this could not be evaluated.
34
35

36
37 A second issue regarding generalisability is the intensity of anticoagulation used in
38
39 the Netherlands. To avoid, particularly, under-anticoagulation, the Dutch anticoagulation
40
41 clinics use a therapeutic range which is 0.5 INR wider towards a higher intensity than the
42
43 conventionally employed target ranges in other countries (e.g. INR 2.0-3.5 vs. INR 2.0-3.0).
44
45 The target ranges that were used were 0.5 INR higher (e.g. INR 2.5-3.5 vs. INR 2.0-3.0).
46
47 Despite the higher target ranges, the percentage of time within the target range as observed
48
49 in our study (median ITTR 43%) was comparable to those reported in previous studies
50
51 (Ansell *et al*, 2008; Fihn *et al*, 2003). The percentage of time with an INR above 5.0 was
52
53 limited to only 3% of treatment time. Furthermore, with an absolute risk of major bleeding of
54
55 1.4 per 100 person-years, in the setting of a specialized anticoagulation clinic this strategy
56
57 did not lead to excessive major bleeding.
58
59
60

1
2
3
4
5 Therefore, in our opinion, the observed association of both poor anticoagulation and
6 minor bleeding with major bleeding is still relevant for VKA therapy today.
7

8
9 In conclusion, minor bleeding is associated with subsequent major bleeding. The
10 occurrence of a minor bleed should increase the awareness towards a potentially high-risk
11 situation. In this, the achieved level of anticoagulation should also be considered, not just the
12 INR at the time of the minor bleed, but especially the amount of over-anticoagulation during
13 the preceding treatment period. In our study, we used the percentage of time above INR 5.0
14 during a 30-day period.
15
16
17
18
19
20
21

22 In line with this awareness, a renewed risk-benefit assessment should be performed.
23 Whether a lower intensity of anticoagulation might be more suitable for these high-risk
24 patients, without compromising the efficacy of VKA therapy to prevent thromboembolic
25 complications is speculative. In this, also VKA as the anticoagulant drug of choice could be
26 reconsidered. For some patients, no anticoagulant agent, aspirin, or – in the near future – an
27 oral II or Xa inhibitor might be a more suitable option.
28
29
30
31
32
33
34
35
36
37
38
39

40 Authorship contributions:

41
42
43 Veeger, Piersma-Wichers and Hillege designed the research study. Piersma-Wichers
44 contributed to data collection. Analysis was performed by Veeger. Veeger and Meijer drafted
45 the manuscript. All authors participated in the interpretation and presentation of the study
46 and approved the final version of the manuscript.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

- Albers, G.W., Diener, H.C., Frison, L., Grind, M., Nevinson, M., Partridge, S., Halperin, J.L., Horrow, J., Olsson, S.B., Petersen, P., & Vahanian, A. (2005) Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. *JAMA*, **293**, 690-698.
- Allison, P.D. (1995) *Survival Analysis Using the SAS® System: A Practical Guide*, pp. 1-292. Cary, NC: SAS Institute Inc..
- Ansell, J., Hirsh, J., Hylek, E., Jacobson, A., Crowther, M., & Palareti, G. (2008) Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest*, **133**, 160S-198S.
- Azar, A.J., Cannegieter, S.C., Deckers, J.W., Briet, E., van Bergen, P.F., Jonker, J.J., & Rosendaal, F.R. (1996) Optimal intensity of oral anticoagulant therapy after myocardial infarction. *J Am. Coll. Cardiol.*, **27**, 1349-1355.
- Beyth, R.J., Quinn, L.M., & Landefeld, C.S. (1998) Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. *Am.J.Med.*, **105**, 91-99.
- Connolly, S.J., Ezekowitz, M.D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P.A., Themeles, E., Varrone, J., Wang, S., Alings, M., Xavier, D., Zhu, J., Diaz, R., Lewis, B.S., Darius, H., Diener, H.C., Joyner, C.D., & Wallentin, L. (2009) Dabigatran versus warfarin in patients with atrial fibrillation. *N.Engl.J.Med.*, **361**, 1139-1151.
- DiMarco, J.P., Flaker, G., Waldo, A.L., Corley, S.D., Greene, H.L., Safford, R.E., Rosenfeld, L.E., Mitrani, G., & Nemeth, M. (2005) Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. *Am.Heart J.*, **149**, 650-656.
- Fihn, S.D., Gadisseur, A.A., Pasterkamp, E., van der Meer, F.J., Breukink-Engbers, W.G., Geven-Boere, L.M., van Meegen, E., Vries-Goldschmeding, H., Antheunissen-Anneveld, I., van't Hoff, A.R., Harderman, D., Smink, M., & Rosendaal, F.R. (2003) Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus phenprocoumon. *Thromb.Haemost.*, **90**, 260-266.
- Gage, B.F. & Lesko, L.J. (2008) Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. *J.Thromb.Thrombolysis.*, **25**, 45-51.
- Go, A.S., Hylek, E.M., Chang, Y., Phillips, K.A., Henault, L.E., Capra, A.M., Jensvold, N.G., Selby, J.V., & Singer, D.E. (2003) Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? *JAMA*, **290**, 2685-2692.
- Hermida, J., Zarza, J., Alberca, I., Montes, R., Lopez, M.L., Molina, E., & Rocha, E. (2002) Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol. *Blood*, **99**, 4237-4239.
- Hylek, E.M., Evans-Molina, C., Shea, C., Henault, L.E., & Regan, S. (2007) Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. *Circulation*, **115**, 2689-2696.
- Kucher, N., Connolly, S., Beckman, J.A., Cheng, L.H., Tsilimingras, K.V., Fanikos, J., & Goldhaber, S.Z. (2004) International normalized ratio increase before warfarin-associated hemorrhage - Brief and subtle. *Archives of Internal Medicine*, **164**, 2176-2179.

- 1
2
3
4
5 Kuijjer,P.M., Hutten,B.A., Prins,M.H., & Buller,H.R. (1999) Prediction of the risk of bleeding during
6 anticoagulant treatment for venous thromboembolism. *Arch.Intern.Med.*, **159**, 457-460.
7
8 Linkins,L.A., Choi,P.T., & Douketis,J.D. (2003) Clinical impact of bleeding in patients taking oral
9 anticoagulant therapy for venous thromboembolism: a meta-analysis. *Ann.Intern.Med.*, **139**,
10 893-900.
11
12 McCormick,D., Gurwitz,J.H., Goldberg,R.J., Becker,R., Tate,J.P., Elwell,A., & Radford,M.J. (2001)
13 Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care
14 setting. *Archives of Internal Medicine*, **161**, 2458-2463.
15
16 Olsson,S.B. (2003) Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared
17 with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised
18 controlled trial. *Lancet*, **362**, 1691-1698.
19
20 Palareti,G. & Cosmi,B. (2009) Bleeding with anticoagulation therapy - who is at risk, and how best to
21 identify such patients. *Thromb.Haemost.*, **102**, 268-278.
22
23 Palareti,G., Leali,N., Coccheri,S., Poggi,M., Manotti,C., D'Angelo,A., Pengo,V., Erba,N., Moia,M.,
24 Ciavarella,N., Devoto,G., Berrettini,M., & Musolesi,S. (1996) Bleeding complications of oral
25 anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian
26 Study on Complications of Oral Anticoagulant Therapy. *Lancet*, **348**, 423-428.
27
28 Palareti,G., Legnani,C., Guazzaloca,G., Lelia,V., Cosmi,B., Lunghi,B., Marchetti,G., Poli,D., &
29 Pengo,V. (2005) Risks factors for highly unstable response to oral anticoagulation: a case-
30 control study. *British Journal of Haematology*, **129**, 72-78.
31
32 Penning-van Beest,F.J.A., van Meegen,E., Rosendaal,F.R., & Stricker,B.H.C. (2001) Characteristics
33 of anticoagulant therapy and comorbidity related to overanticoagulation. *Thrombosis and*
34 *Haemostasis*, **86**, 569-574.
35
36 Reynolds,M.W., Fahrbach,K., Hauch,O., Wygant,G., Estok,R., Cella,C., & Nalysnyk,L. (2004) Warfarin
37 anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and
38 metaanalysis. *Chest*, **126**, 1938-1945.
39
40 Rosendaal,F.R., Cannegieter,S.C., van der Meer,F.J., & Briet,E. (1993) A method to determine the
41 optimal intensity of oral anticoagulant therapy. *Thromb.Haemost.*, **69**, 236-239.
42
43 Samsa,G.P., Matchar,D.B., Phillips,D.L., & McGrann,J. (2002) Which approach to anticoagulation
44 management is best? Illustration of an interactive mathematical model to support informed
45 decision making. *J.Thromb.Thrombolysis*, **14**, 103-111.
46
47 Schulman,S. & Kearon,C. (2005) Definition of major bleeding in clinical investigations of
48 antihemostatic medicinal products in non-surgical patients. *J.Thromb.Haemost.*, **3**, 692-694.
49
50 Schulman,S., Beyth,R.J., Kearon,C., & Levine,M.N. (2008) Hemorrhagic Complications of
51 Anticoagulant and Thrombolytic Treatment: American College of Chest Physicians Evidence-
52 Based Clinical Practice Guidelines (8th Edition). *Chest*, **133**, 257S-298S.
53
54 Shireman,T.I., Mahnken,J.D., Howard,P.A., Kresowik,T.F., Hou,Q., & Ellerbeck,E.F. (2006)
55 Development of a contemporary bleeding risk model for elderly warfarin recipients. *Chest*,
56 **130**, 1390-1396.
57
58 The Stroke Prevention in Atrial Fibrillation Investigators (1996) Bleeding during antithrombotic therapy
59 in patients with atrial fibrillation. *Arch.Intern.Med.*, **156**, 409-416.
60
van der Meer,F.J., Rosendaal,F.R., Vandenbroucke,J.P., & Briet,E. (1993) Bleeding complications in
oral anticoagulant therapy. An analysis of risk factors. *Arch.Intern.Med.*, **153**, 1557-1562.

- 1
2
3
4
5 van der Meer,F.J.M., Briet,E., Vandenbroucke,J.P., Sramek,D.I., Versluijs,M.H.P.M., &
6 Rosendaal,F.R. (1997) The role of compliance as a cause of instability in oral anticoagulant
7 therapy. *British Journal of Haematology*, **98**, 893-900.
8
9 van Es,R.F., Jonker,J.J., Verheugt,F.W., Deckers,J.W., & Grobbee,D.E. (2002) Aspirin and coumadin
10 after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. *Lancet*,
11 **360**, 109-113.
12
13 Veeger,N.J., Piersma-Wichers,M., Hillege,H.L., Crijs,H.J., & van der Meer,J. (2006) Early detection of
14 patients with a poor response to vitamin K antagonists: the clinical impact of individual time
15 within target range in patients with heart disease. *J.Thromb.Haemost.*, **4**, 1625-1627.
16
17 Veeger,N.J., Piersma-Wichers,M., Tijssen,J.G., Hillege,H.L., & van der Meer,J. (2005) Individual time
18 within target range in patients treated with vitamin K antagonists: main determinant of quality
19 of anticoagulation and predictor of clinical outcome. a retrospective study of 2300 consecutive
20 patients with venous thromboembolism. *British Journal of Haematology*, **128**, 513-519.
21
22 White,R.H., McKittrick,T., Takakuwa,J., Callahan,C., McDonell,M., & Fihn,S. (1996) Management and
23 prognosis of life-threatening bleeding during warfarin therapy. National Consortium of
24 Anticoagulation Clinics. *Arch.Intern.Med.*, **156**, 1197-1201.
25
26 Wilkinson,G.R. (2005) Drug therapy - Drug metabolism and variability among patients in drug
27 response. *New England Journal of Medicine*, **352**, 2211-2221.
28
29 Wittkowsky,A.K. (2005) Factors associated with INR elevation and bleeding complications during
30 warfarin therapy. *Archives of Internal Medicine*, **165**, 703.
31
32 Wittkowsky,A.K. & Devine,E.B. (2004) Frequency and causes of overanticoagulation and
33 underanticoagulation in patients treated with warfarin. *Pharmacotherapy*, **24**, 1311-1316.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Legend

Table 1 Patient characteristics and anticoagulation data.

Table 2 Type of major bleeds.

Table 3 Major bleeding.

Figure 1 Hazard ratios of major bleeding, from survival analysis using a piecewise exponential model. Presented variables were included in final model.

For Peer Review

Table 1 Patients' characteristics and anticoagulation data.

	Total
	N=5898
Patients' characteristics	
Age, years *	68 (37-86)
Male, %	52
Diabetes mellitus, %	9
Malignancy, %	4
Concomitant drugs, %	
low dose aspirin	3
beta blockers	5
calcium antagonists	7
nitrates	1
antiarrhythmic drugs	8
diuretics	10
lipid lowering drugs	6
oral contraceptives/HRT [†]	1
NSAIDs [#]	7
Anticoagulation data *	
Follow-up time (months)	9.1 (1.4-11.8)
Number of INRs	20 (7-35)
Time between INRs (days)	13 (3-28)
INR [‡]	3.0 (1.6-5.7)
Time with INR > 5.0 (%)	3 (0-23)
ITTR (%) [§]	43 (13-75)

* median (90% central range); † hormone replacement therapy; # Non-steroidal anti-inflammatory drugs; ‡ International Normalized Ratio; § Individual Time within Target Range; || INR stability is expressed as absolute daily INR change.


Table 2 Type of minor bleeds.

Minor bleeds N (%)	
Total	1501 (100.0)
haematoma	595 (39.6)
nose bleed	408 (27.2)
conjunctiva bleed	163 (10.9)
haematuria	143 (9.5)
gastrointestinal bleed	68 (4.5)
haemoptoe	32 (2.1)
vaginal bleed	28 (1.9)
muscular bleed	12 (0.8)
other	52 (3.5)

Table 3 Major bleeding.

TYPE OF EVENT *	Minor bleeding		Total n=5898
	Yes n=1015	No n=4883	
Major bleeding n (%)	18 (1.8)	38 (0.8)	56 (0.9)
non-fatal gastrointestinal	5	8	13
fatal gastrointestinal	1	1	2
non-fatal intracranial	1	4	5
fatal intracranial	2	5	7
intra-ocular	0	3	3
other major bleeding#	9	17	26
incidence rate (95% CI) per 100 patient-years	2.3 (1.4-3.7)	1.2 (0.9-1.7)	1.4 (1.1-1.9)

* The number of patients with at least one event is presented. In case of multiple bleeding, the first event was considered. # Other bleeding adjudicated as major were haemoptoe (6; 2 in patients with a prior minor bleed and 4 in patients without a prior minor bleed), haematuria (4; 1-3), haematoma (2; 1-1), vaginal bleed (6; 2-4), nose bleed (2; 1-1), intra-articular bleed (1; 1-0) and miscellaneous (5; 1-4).



* Time-dependent variable.

Over-anticoagulation was defined as the upper quartile of percentages of time above INR 5.0, i.e. 9% or more above INR 5.0.

Figure 1 Hazard ratios of major bleeding, from survival analysis using a multivariable piecewise exponential model. Presented variables were included in the final model.
959x479mm (150 x 150 DPI)

Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60